Literature DB >> 17197488

PDE-5 inhibitors lower portal and pulmonary pressure in portopulmonary hypertension.

P Deibert, H Bremer, M Roessle, A-K Kurz-Schmieg, W Kreisel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17197488     DOI： 10.1183/09031936.00110006

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  5 in total

Review 1.  Treatment Barriers in Portopulmonary Hypertension.

Authors:  Batool AbuHalimeh; Michael J Krowka; Adriano R Tonelli
Journal:  Hepatology       Date:  2018-12-18       Impact factor: 17.425

2.  Tadalafil: the evidence for its clinical potential in the treatment of pulmonary arterial hypertension.

Authors:  Stuart D Katz
Journal:  Core Evid       Date:  2008-07-31

3.  Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease.

Authors:  Kari E Roberts; Michael B Fallon; Michael J Krowka; Robert S Brown; James F Trotter; Inga Peter; Hocine Tighiouart; James A Knowles; Daniel Rabinowitz; Raymond L Benza; David B Badesch; Darren B Taichman; Evelyn M Horn; Steven Zacks; Neil Kaplowitz; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2009-02-12       Impact factor: 21.405

4.  Sildenafil monotherapy in portopulmonary hypertension can facilitate liver transplantation.

Authors:  Anna R Hemnes; Ivan M Robbins
Journal:  Liver Transpl       Date:  2009-01       Impact factor: 5.799

5.  Phosphodiesterase-5 inhibitors have distinct effects on the hemodynamics of the liver.

Authors:  Leonie Halverscheid; Peter Deibert; René Schmidt; Hubert E Blum; Torsten Dunkern; Benedikt H J Pannen; Wolfgang Kreisel
Journal:  BMC Gastroenterol       Date:  2009-09-18       Impact factor: 3.067
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.